Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 7/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | NMT2 | O60551 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.32 |
| ▸ | NPY4R | P50391 | 6/20 | 0.32 |
| ▸ | NPY1R | P25929 | 4/20 | 0.32 |
| ▸ | NPY2R | P49146 | 3/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22067692 | 0.91 | FURIN (0.38) | FURINSIRT5NMT2NMT1C3AR1 | |
| SCHEMBL23126444 | 0.91 | FURIN (0.38) | FURINSIRT5NMT2NMT1C3AR1 | |
| SCHEMBL21788282 | 0.91 | FURIN (0.38) | FURINSIRT5NMT2NMT1C3AR1 | |
| SCHEMBL20834995 | 0.89 | SIRT5 (0.34) | FURINSIRT5C3AR1NPY4RNPY1R | |
| SCHEMBL22692371 | 0.88 | FURIN (0.32) | FURINC3AR1 | |
| SCHEMBL27352679 | 0.86 | FURIN (0.38) | FURINSIRT5NMT2NMT1C3AR1 | |
| SCHEMBL21788077 | 0.86 | FURIN (0.38) | FURINSIRT5NMT2NMT1C3AR1 | |
| SCHEMBL25942881 | 0.84 | FURIN (0.36) | FURINSIRT5NMT2NMT1C3AR1 | |
| SCHEMBL21788004 | 0.82 | FURIN (0.36) | FURINSIRT5NMT2NMT1C3AR1 | |
| SCHEMBL23900963 | 0.82 | FURIN (0.36) | FURINSIRT5NMT2NMT1C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| US-20200069814-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069814-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | FURIN 2643/4885SIRT5 3829/4885NMT2 1338/4885 |
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | BTN3A1, ANTXR2, CLTA | FURIN 1970/4885SIRT5 4250/4885NMT2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.